|
1
|
Provencio M, Isla D, Sánchez A and Cantos
B: Inoperable stage III non-small cell lung cancer: Current
treatment and role of vinorelbine. J Thorac Dis. 3:197–204.
2011.PubMed/NCBI
|
|
2
|
Zeng H, Zheng R, Guo Y, Zhang S, Zou X,
Wang N, Zhang L, Tang J, Chen J, Wei K, et al: Cancer survival in
China, 2003–2005: A population-based study. Int J Cancer.
136:1921–1930. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Non-Small Cell Lung Cancer Treatment
(PDQ®): National Cancer Institute (US). 2013, https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq
|
|
4
|
Giaccone G, Herbst RS, Manegold C,
Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel
J, Pluzanska A, et al: Gefitinib in combination with gemcitabine
and cisplatin in advanced non-small-cell lung cancer: A phase III
trial-INTACT 1. J Clin Oncol. 22:777–784. 2004. View Article : Google Scholar
|
|
5
|
Ciardiello F, Caputo R, Bianco R, Damiano
V, Pomatico G, De Placido S, Bianco AR and Tortora G: Antitumor
effect and potentiation of cytotoxic drugs activity in human cancer
cells by ZD-1839 (Iressa), an epidermal growth factor
receptor-selective tyrosine kinase inhibitor. Clin Cancer Res.
6:2053–2063. 2000.
|
|
6
|
Crombet T, Torres L, Neninger E, Catalá M,
Solano ME, Perera A, Torres O, Iznaga N, Torres F, Pérez R and Lage
A: Pharmacological evaluation of humanized anti-epidermal growth
factor receptor, monoclonal antibody h-R3, in patients with
advanced epithelial-derived cancer. J Immunother. 26:139–148. 2003.
View Article : Google Scholar
|
|
7
|
Keedy VL, Temin S, Somerfield MR, Beasley
MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA and
Giaccone G: American Society of Clinical Oncology provisional
clinical opinion: Epidermal growth factor receptor (EGFR) mutation
testing for patients with advanced non-small-cell lung cancer
considering first-line EGFR tyrosine kinase inhibitor therapy. J
Clin Oncol. 29:2121–2127. 2011. View Article : Google Scholar
|
|
8
|
Stella GM, Scabini R, Inghilleri S, Cemmi
F, Corso S, Pozzi E, Morbini P, Valentini A, Dore R, Ferrari S, et
al: EGFR and KRAS mutational profiling in fresh non-small cell lung
cancer (NSCLC) cells. J Cancer Res Clin Oncol. 139:1327–1335. 2013.
View Article : Google Scholar
|
|
9
|
Raben D, Helfrich B and Bunn PA Jr:
Targeted therapies for non-small-cell lung cancer: Biology,
rationale, and preclinical results from a radiation oncology
perspective. Int J Radiat Oncol Biol Phys. 59 Suppl 2:S27–S38.
2004. View Article : Google Scholar
|
|
10
|
Cappuzzo F, Hirsch FR, Rossi E, Bartolini
S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini
I, et al: Epidermal growth factor receptor gene and protein and
gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer
Inst. 97:643–655. 2005. View Article : Google Scholar
|
|
11
|
Mendelsohn J and Baselga J: Status of
epidermal growth factor receptor antagonists in the biology and
treatment of cancer. J Clin Oncol. 21:2787–2799. 2003. View Article : Google Scholar
|
|
12
|
Yoshida T, Zhang G and Haura EB: Targeting
epidermal growth factor receptor: Central signaling kinase in lung
cancer. Biochem Pharmacol. 80:613–623. 2010. View Article : Google Scholar
|
|
13
|
Xu N, Fang W, Mu L, Tang Y, Gao L, Ren S,
Cao D, Zhou L, Zhang A, Liu D, et al: Overexpression of wildtype
EGFR is tumorigenic and denotes a therapeutic target in non-small
cell lung cancer. Oncotarget. 7:3884–3896. 2016.
|
|
14
|
Sabattini S, Mancini FR, Marconato L,
Bacci B, Rossi F, Vignoli M and Bettini G: EGFR overexpression in
canine primary lung cancer: Pathogenetic implications and impact on
survival. Vet Comp Oncol. 12:237–248. 2014. View Article : Google Scholar
|
|
15
|
Tebbutt N, Pedersen MW and Johns TG:
Targeting the ERBB family in cancer: Couples therapy. Nat Rev
Cancer. 13:663–673. 2013. View
Article : Google Scholar
|
|
16
|
Bebb G, Smith C, Rorke S, Boland W,
Nicacio L, Sukhoo R and Brade A: Phase I clinical trial of the
anti-EGFR monoclonal antibody nimotuzumab with concurrent external
thoracic radiotherapy in Canadian patients diagnosed with stage
IIb, III or IV non-small cell lung cancer unsuitable for radical
therapy. Cancer Chemother Pharmacol. 67:837–845. 2011. View Article : Google Scholar
|
|
17
|
Rojo F, Gracias E, Villena N, Cruz T,
Corominas JM, Corradino I, Cedeño M, Campas C, Osorio M, Iznaga N,
et al: Pharmacodynamic trial of nimotuzumab in unresectable
squamous cell carcinoma of the head and neck: A SENDO Foundation
study. Clin Cancer Res. 16:2474–2482. 2010. View Article : Google Scholar
|
|
18
|
Crombet T, Osorio M, Cruz T, Roca C, del
Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J,
Renginfo E, et al: Use of the humanized anti-epidermal growth
factor receptor monoclonal antibody h-R3 in combination with
radiotherapy in the treatment of locally advanced head and neck
cancer patients. J Clin Oncol. 22:1646–1654. 2004. View Article : Google Scholar
|
|
19
|
Ramos TC, Figueredo J, Catala M, González
S, Selva JC, Cruz TM, Toledo C, Silva S, Pestano Y, Ramos M, et al:
Treatment of high-grade glioma patients with the humanized
anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report
from a phase I/II trial. Cancer Biol Ther. 5:375–379. 2006.
View Article : Google Scholar
|
|
20
|
Ma NY, Cai XW, Fu XL, Li Y, Zhou XY, Wu
XH, Hu XC, Fan M, Xiang JQ, Zhang YW, et al: Safety and efficacy of
nimotuzumab in combination with radiotherapy for patients with
squamous cell carcinoma of the esophagus. Int J Clin Oncol.
19:297–302. 2014. View Article : Google Scholar
|
|
21
|
Herbst RS and Bunn PA Jr: Targeting the
epidermal growth factor receptor in non-small cell lung cancer.
Clin Cancer Res. 9:5813–5824. 2003.
|
|
22
|
Raben D, Helfrich B, Chan DC, Ciardiello
F, Zhao L, Franklin W, Barón AE, Zeng C, Johnson TK and Bunn PA Jr:
The effects of cetuximab alone and in combination with radiation
and/or chemotherapy in lung cancer. Clin Cancer Res. 11:795–805.
2005.
|
|
23
|
Cascone T, Morelli MP and Ciardiello F:
Small molecule epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors in non-small cell lung cancer. Ann Oncol. 17
Suppl 2:ii46–ii48. 2006. View Article : Google Scholar
|
|
24
|
Babu KG, Prabhash K, Vaid AK, Sirohi B,
Diwakar RB, Rao R, Kar M, Malhotra H, Nag S, Goswami C, et al:
Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced
non-small-cell lung cancer: A multicenter, randomized, open-label
Phase II study. Onco Targets Ther. 7:1051–1060. 2014. View Article : Google Scholar
|
|
25
|
Diaz Miqueli A, Blanco R, Garcia B, Badia
T, Batista AE, Alonso R and Montero E: Biological activity in vitro
of anti-epidermal growth factor receptor monoclonal antibodies with
different affinities. Hybridoma (Larchmt). 26:423–431. 2007.
View Article : Google Scholar
|
|
26
|
Akashi Y, Okamoto I, Iwasa T, Yoshida T,
Suzuki M, Hatashita E, Yamada Y, Satoh T, Fukuoka M, Ono K and
Nakagawa K: Enhancement of the antitumor activity of ionising
radiation by nimotuzumab, a humanised monoclonal antibody to the
epidermal growth factor receptor, in non-small cell lung cancer
cell lines of differing epidermal growth factor receptor status. Br
J Cancer. 98:749–755. 2008. View Article : Google Scholar
|
|
27
|
Maioli E, Torricelli C, Fortino V,
Carlucci F, Tommassini V and Pacini A: Critical appraisal of the
MTT assay in the presence of rottlerin and uncouplers. Biol Proced
Online. 11:227–240. 2009. View Article : Google Scholar
|
|
28
|
Vindeløv LL, Christensen IJ and Nissen NI:
A detergent-trypsin method for the preparation of nuclei for flow
cytometric DNA analysis. Cytometry. 3:323–327. 1983. View Article : Google Scholar
|
|
29
|
Casimiro MC, Velasco-Velázquez M,
Aguirre-Alvarado C and Pestell RG: Overview of cyclins D1 function
in cancer and the CDK inhibitor landscape: Past and present. Expert
Opin Investig Drugs. 23:295–304. 2014. View Article : Google Scholar
|
|
30
|
Ramakrishnan MS, Eswaraiah A, Crombet T,
Piedra P, Saurez G, Iyer H and Arvind AS: Nimotuzumab, a promising
therapeutic monoclonal for treatment of tumors of epithelial
origin. MAbs. 1:41–48. 2009. View Article : Google Scholar
|
|
31
|
Massimino M, Bode U, Biassoni V and
Fleischhack G: Nimotuzumab for pediatric diffuse intrinsic pontine
gliomas. Expert Opin Biol Ther. 11:247–256. 2011. View Article : Google Scholar
|
|
32
|
Ramos-Suzarte M, Lorenzo-Luaces P, Lazo
NG, Perez ML, Soriano JL, Gonzalez CE, Hernadez IM, Albuerne YÁ,
Moreno BP, Alvarez ES, et al: Treatment of malignant,
non-resectable, epithelial origin esophageal tumours with the
humanized anti-epidermal growth factor antibody nimotuzumab
combined with radiation therapy and chemotherapy. Cancer Biol Ther.
13:600–605. 2012. View Article : Google Scholar
|
|
33
|
Wang Y, Pan L, Sheng XF, Chen S and Dai
JZ: Nimotuzumab, a humanized monoclonal antibody specific for the
EGFR, in combination with temozolomide and radiation therapy for
newly diagnosed glioblastoma multiforme: First results in Chinese
patients. Asia Pac J Clin Oncol. 12:e23–e29. 2016. View Article : Google Scholar
|
|
34
|
Zhao KL, Hu XC, Wu XH, Fu XL, Fan M and
Jiang GL: A phase I dose escalation study of nimotuzumab in
combination with concurrent chemoradiation for patients with
locally advanced squamous cell carcinoma of esophagus. Invest New
Drugs. 30:1585–1590. 2012. View Article : Google Scholar
|
|
35
|
Ji YH, Yang XY, Wu JQ, Huo XQ, Li WW, Li
GJ, Mu YL and Lu P: Nimotuzumab with cisplatin or fluorouracil on
human esophageal squamous cell carcinoma EC1 cells. Eur Rev Med
Pharmacol Sci. 19:586–591. 2015.
|
|
36
|
Du F, Zheng Z, Shi S, Jiang Z, Qu T, Yuan
X, Sun Y, Song Y, Yang L, Zhao J, et al: S-1 and cisplatin with or
without nimotuzumab for patients with untreated unresectable or
metastatic gastric cancer: A randomized, open-label phase 2 trial.
Medicine (Baltimore). 94:e9582015. View Article : Google Scholar
|
